Exercise, Gut Microbiota in Sedentary Adults With Overweight
Effect of Two Exercise Programme on Gut Microbiota, Hepatic Metabolism and Adipokines in Sedentary Adults With Overweight
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Cundinamarca
-
Bogotá, Cundinamarca, Colombia, 111221
- Robinson Ramírez-Vélez
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy
- Sedentary males
- BMI>25 kg/m2, on a stable body weight for the last 3 months
Exclusion Criteria:
- Acute or chronic illness
- Use of antibiotics the past 2 months
- Smoking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HIIT group
The HIIT modality consisted of 30-40 minutes (min) of steady-state, high-intensity training 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 85% to 95% of the individual's maximum oxygen consumption rate (VO2max).
Exercise will be performed at three sessions per week.
All sessions will be supervised by an exercise physiologist during 6-weeks.
|
Physical Training
Other Names:
|
|
Active Comparator: SIT group
The SIT modality consisted of 6 to 10 repetitions of a 30 s segment of all-out exercise interspersed with 2 min of recovery, 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 90% to 95% of the individual's maximum oxygen consumption rate (VO2max).
|
Physical Training
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gut microbiota
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline in the gut microbiota composition measured by amplicon sequencing
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Plasma metabolomic profile
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline in the metabolomic profile will be also evaluated by a HPLC-MS approach
|
Baseline, and 6 weeks immediately after the interventions ends
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma hepatokines
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline in the Chemerin will be measured using ELISA kits
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Plasma hepatokines
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline in the Selenoprotein P will be measured using ELISA kits
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Plasma hepatokines
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline in the Fetuin-A will be measured using ELISA kits
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Plasma hepatokines
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline in the FGF21 (fibroblast growth factor 21) Leukocyte cell-derived will be measured using ELISA kits
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Glucose
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline will be also evaluated by a spectroscopy
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Insulin
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline will be also evaluated by a ELISA
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Glycated hemoglobin
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline will be also evaluated by a ELISA
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Bioinflammatory blood markers
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline measure of plasma IL-1 concentrations measured ELISA
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Bioinflammatory blood markers
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline measure of plasma IL6 concentrations measured ELISA
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Bioinflammatory blood markers
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline measure of plasma TNF-alfa concentrations measured ELISA
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Bioinflammatory blood markers
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Change from Baseline measure of plasma CRP concentrations measured ELISA
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Body composition
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Differences in body weight (kilograms) measured by DXA
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Body composition
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Differences in body fat (%) measured by DXA
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Body composition
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Differences in mass muscle measured by DXA
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Physical fitness
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Differences in Muscular strength (handgrip test) in kg
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Physical fitness
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Differences in Maximum Oxygen Consumption (VO2 max K5 Gas Analyser) in ml/kg/min
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Energy substrate oxidation
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Fat and carbohydrate oxidation in the fasted and postprandial state measured before and after the interventions using indirect calorimetry (K5 cosmed)
|
Baseline, and 6 weeks immediately after the interventions ends
|
|
Resting Metabolic Rate
Time Frame: Baseline, and 6 weeks immediately after the interventions ends
|
Resting metabolic rate was measured before and after the interventions (K5 Cosmed)
|
Baseline, and 6 weeks immediately after the interventions ends
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DVO005-1-338-CEI882
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.